J. Gogate

发表

Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.

M. Trivedi, T. Carmody, A. Dibernardo, 2022, International journal of methods in psychiatric research.

Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.

K. Mahaffey, G. Figtree, T. Greene, 2022, Journal of the American College of Cardiology.

Treatment Effect With Paliperidone Palmitate Compared With Oral Antipsychotics in Black/African American Patients With Schizophrenia and a History of Criminal Justice System Involvement: A Post Hoc Analysis of the PRIDE Study.

D. Henderson, Edward Kim, J. Gogate, 2021, The Journal of clinical psychiatry.

Response to higher doses of interferon alfa‐2b in patients with chronic hepatitis C: A randomized multicenter trial

E. Schiff, J. Albrecht, G. Davis, 1996, Hepatology.

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

J. Perfect, C. White, R. Greene, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.

D. Skiest, I. Sanne, W. Greaves, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*

S. Opal, A. Wittek, M. Tidswell, 2010, Critical care medicine.

Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial

K. Mahaffey, M. Weir, R. Correa-Rotter, 2021, Diabetes, obesity & metabolism.

Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564) and on Other Therapies for Severe Sepsis

S. Opal, A. Kalil, S. LaRosa, 2011, Shock.

142 Withdrawal Symptom Assessment in an Esketamine Safety Study in Patients with Treatment-resistant Depression

W. Drevets, A. Dibernardo, A. Krystal, 2020, CNS Spectrums.

Self-reported review of the value of esketamine in patients with treatment-resistant depression: Understanding the patient experience in the STRIVE Study

C. Demuro, E. Daly, J. Abell, 2020, Psychiatry Research.

Phase 2 trial of eritoran tetrasodium ( E 5564 ) , a Toll-like receptor 4 antagonist , in patients with severe sepsis *

S. Opal, A. Wittek, M. Tidswell, 2009 .

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study

M. Mathews, S. Gopal, Edward Kim, 2020, Neuropsychiatric disease and treatment.

NDT_A_226296 681..690

Ashutosh Kumar Singh, M. Mathews, S. Gopal, 2020 .

Response to higher doses of interferon alfa‐2b in patients with chronic hepatitis C: A randomized multicenter trial

E. Schiff, J. Albrecht, G. Davis, 1996, Hepatology.

Posaconazole vs Standard Azole (FLU/ITRA) Therapy for Prophylaxis of Invasive Fungal Infections (IFIs) among High-Risk Neutropenic Patients: Results of a Randomized, Multicenter Trial.

J. Perfect, T. Walsh, J. Maertens, 2005 .

A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS.

D. Skiest, I. Sanne, W. Greaves, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.